Progranulin is a secreted protein with important functions in processes including immune and inflammatory response, metabolism and embryonic development. The present study aimed at identification of genetic factors determining progranulin concentrations. We conducted a genome-wide association meta-analysis for serum progranulin in three independent cohorts from Europe: Sorbs (N ¼ 848) and KORA (N ¼ 1628) from Germany and PPP-Botnia (N ¼ 335) from Finland (total N ¼ 2811). Single nucleotide polymorphisms (SNPs) associated with progranulin levels were replicated in two additional German cohorts: LIFE-Heart Study (Leipzig; N ¼ 967) and Metabolic Syndrome Berlin Potsdam (Berlin cohort; N ¼ 833). We measured mRNA expression of genes in peripheral blood mononuclear cells (PBMC) by micro-arrays and performed mRNA expression quantitative trait and expression-progranulin association studies to functionally substantiate identified loci. Finally, we conducted siRNA silencing experiments in vitro to validate potential candidate genes within the associated loci. Heritability of circulating progranulin levels was estimated at 31.8% and 26.1% in the Sorbs and LIFE-Heart cohort, respectively. SNPs at three loci reached study-wide significance (rs660240 in CELSR2-PSRC1-MYBPHL-SORT1, rs4747197 in CDH23-PSAP and rs5848 in GRN) explaining 19.4%/15.0% of the variance and 61%/57% of total heritability in the Sorbs/LIFE-Heart Study. The strongest evidence for association was at rs660240 (P ¼ 5.75 Â 10 À50 ), which was also associated with mRNA expression of PSRC1 in PBMC (P ¼ 1.51 Â 10 À21 ). Psrc1 knockdown in murine preadipocytes led to a consecutive 30% reduction in progranulin secretion. In conclusion, the present meta-GWAS combined with mRNA expression identified three loci associated with progranulin and supports the role of PSRC1 in the regulation of progranulin secretion.
Introduction
Progranulin is an 88kDa precursor protein of the family of secreted granulins involved in angiogenesis, tumorigenesis but also in neurodegenerative and metabolic disease (1) . Moreover, progranulin is proposed to be a marker of chronic inflammation in obesity and type 2 diabetes characterized by omental adipose tissue macrophage infiltration (2) . Progranulin has been shown to affect plasma lipoprotein metabolism, risk for atherosclerosis and chronic inflammatory status (3) (4) (5) . However, exact mechanisms linking all these diverse functions have not been elucidated so far.
Progranulin is encoded by the granulin gene (GRN) on chromosome 17q. Mutations in GRN result in reduced serum progranulin (6) and have been shown to be associated with frontotemporal dementia (FTD) and Alzheimer's disease (7) (8) (9) (10) . However, even in non-carriers of the GRN mutations, there is a marked variation in circulating progranulin concentrations, thus challenging studies aiming at identification of further genetic factors involved in progranulin biology. A previous genome-wide scan in 533 subjects revealed an association of common variation in the CELSR2/PSRC1/MYBPHL/SORT1 locus on chromosome 1p with serum progranulin concentrations. Functional analyses employing overexpression and knockdown of SORT1 in vitro suggested this gene to be the major genetic regulator of serum progranulin levels (11) .
Although the above-mentioned genome-wide association study (GWAS) implied a strong genetic impact on circulating progranulin, a sufficiently powered GWAS for serum progranulin concentration in metabolically well characterized cohorts is still lacking. Therefore, we conducted a meta-analysis of GWAS for serum progranulin in three independent cohorts: the Sorbs (N ¼ 848) and KORA (N ¼ 1628) from Germany and the PPP-Botnia (N ¼ 335) from Finland. We further replicated our findings in two independent cohorts from Germany [LIFE-Heart from Leipzig with N ¼ 967 and MeSyBePo (Metabolic Syndrome Berlin Potsdam) with N ¼ 833]. To identify and elucidate the role of candidate genes in the regulation of progranulin secretion, we performed further in vitro and in vivo analyses using geneexpression data of peripheral blood mononuclear cells (PBMC). These comprised gene-expression quantitative trait locus mapping (eQTL), gene-expression association analysis and corresponding causal inference. Finally, we employed in vitro functional assays to validate potential target genes within the associated loci.
Results

Association of serum progranulin concentrations with obesity and parameters of glucose metabolism in the Sorbs cohort
Serum progranulin concentrations were positively correlated with obesity measures (% of body fat, BMI, WHR), fasting insulin, insulin resistance (HOMA-IR, Stumvoll ISI index) and LDLcholesterol. Interestingly, serum progranulin concentrations were also positively associated with adipocyte fatty acid binding protein (AFABP) and chemerin levels but not with vaspin and adiponectin concentrations (Table 1) . There was no correlation between progranulin levels and renal function ( Table 1) .
Estimation of the heritability of progranulin concentration
The significant degree of relatedness observed in the Sorbs cohort allowed us to estimate the heritability of progranulin concentration, which was 31.8%, using a mixed-model approach proposed by Amin et al. and Aulchenko et al. (12, 13) . A similar heritability was estimated for the LIFE-Heart Study (26.1%).
Genome-wide meta-analysis for association with serum progranulin concentrations
No general inflation of meta-analysis statistics was observed (k ¼ 1.007 for fixed effect model, k ¼ 0.82 for random effects model). Based on the random effects model, 7 SNPs on a unique locus of chromosome 1p13.3 reached genome-wide significance (P < 5.0 Â10 À8 ) in the meta-analysis of Sorbs (N ¼ 848), KORA (N ¼1628) and PPP (N ¼ 335, Table 2 ). All of these SNPs were consistently associated with P < 10 À4 in all three cohorts with the same direction of the effect (Supplementary Material, Table S2 ). The strongest evidence for association was observed for rs660240 within the Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 (CELSR2)-Proline/Serine-Rich Coiled-Coil 1 (PSRC1)-Myosin Binding Protein H-Like (MYBPHL) locus (P ¼ 4.22 Â 10
À15
, beta¼-0.161, Table 2 and Fig. 2 ). All other SNPs of this locus with P < 5.0 Â 10
À8
were in strong to moderate linkage disequilibrium (LD) with rs660240 (minimal r 2 ¼ 0.69 in HapMap CEU). When adjusting progranulin levels for rs660240, the SNPs at this locus were no longer significant in the Sorbs cohort (minimal P-value 0.37), i.e. no independent associations of other SNPs were detected at this locus. The results of the subgroup analyses in males and females were consistent with data in the total cohort (data not shown). No significant interaction of rs660240 and sex was observed (P ¼ 0.78 in the Sorbs cohort).
Of note, a total of 144 SNPs in 24 regions reached P-values <5 Â 10 À5 according to the random effects model. Summary statistics including comprehensive annotation with respect to nearby genes, known eQTL data and links to other GWAS hits can be found in Supplementary Material, Table S2 .
Replication of association signals
Second stage replication analysis in the LIFE-Heart Study We replicated the respective top-hits of the above-mentioned 24 loci in 967 independent samples of the LIFE-Heart Study (14) . All of these 24 SNPs identified at the first-stage GWAS were either directly measured or imputed with high quality, i.e. no proxies were required. Three SNPs were robustly replicated with P-values <1 Â 10 À5 with the same direction of effect as in the meta-GWAS. Statistics of the replicated SNPs are displayed in Table 2 .
Statistics of all SNPs analysed in LIFE-Heart can be found in Supplementary Material, Table S3 . Briefly, replication analysis revealed a clear support of our results at chromosome 1 for the locus CELSR2-PSRC1-MYBPHL-SORT1 with similar effect sizes as observed for the Sorbs and KORA cohort. In addition, we were able to replicate the hits rs4747197 on chromosome 10q22.1 (P ¼ 1.4 Â 10
À6
) and rs5848 on chromosome 17q21.32 (P ¼ 5.6 Â 10 À8 ), both with similar effect sizes as in the initial meta-GWAS (Table 2) .
Third stage replication analysis in Berlin cohort (MeSyBePo)
The three SNPs successfully replicated in LIFE-Heart were finally tested in the Berlin cohort applying a significance threshold of 5%/3. All SNPs fulfilled this requirement and the effect sizes were similar to those of LIFE-Heart and the meta-analysis (Table 2 and Supplementary Material, Table S4 ). A metaanalysis including all 5 studied cohorts (3 discovery þ 2 replication cohorts) resulted in a P ¼ 5.7 Â 10
À12 for rs4747197 in CDH23 (Cadherin-Related 23 -Chr. 10q22.1) and P ¼ 5.3 Â 10 À14 for rs5848 (in GRN-GranulinChr. 17q21.32) (all random effects model, Table 2 and Fig. 3 ). The replicated SNPs explain 19.4% (rs660240: 16.7%, rs4747197: 1.6%, rs5848: 1.0%) of progranulin variance in the Sorbs, i.e. more than 60% of the heritability is covered by these SNPs. Again these findings are supported by the LIFE-Heart Study (total explained variance: 15.0%, rs660240: 10.5%, rs4747197: 1.9%, rs5848: 2.6%, total explained heritability: 57%) and MeSyBePo (total explained variance: 11.7%, rs660240: 10.1%, rs4747197: 0.7%, rs5848: 0.9%, heritability estimates are not available for this study).
Comparison with the GWAS catalogue
In total, we robustly identified three independent genetic associations with progranulin. Comparing these hits with published Adjusted for age, sex and BMI; a P-value cut-off of 5%/3 was applied accounting for three independent association tests. (47) . Glomerular filtration rate (GFR) was calculated using the MDRD formula. ß -Beta coefficient of linear regression model.
GWAS via the GWAS catalogue (downloaded at 2016/06/01) revealed that rs660240 was associated with several phenotypes of lipid metabolism and cardiovascular disease. This SNP was also listed in the first previously reported progranulin GWAS study (11) . The SNP rs5848 was found to be in some LD with rs708382 (r 2 ¼0.59) showing an association with platelet count (15) . However, the latter association was not replicated so far. In the GWAS catalogue, no correlated GWAS hits were found for rs4747197. All results can be found in Supplementary Material, Table S2 .
Gene-expression QTL studies
To further elucidate possible functional roles of the three genetic variants detected, we performed analyses of genomewide PBMC gene-expression data from micro-arrays in Sorbs and in the LIFE-Heart Study.
EQTL results of N ¼ 894 Sorb individuals and N ¼ 4299 individuals from the LIFE-Heart Study including comparisons with the literature are shown in Supplementary Material, Table S5 . Analysis revealed eight eQTLs reaching genome-wide cis/transspecific false discovery rate < 5% in at least one cohort and at least nominal significance in the other cohort with the same direction of effect. Of note, all genome-wide significant eQTLs of the smaller Sorbs study were also found in the LIFE-Heart Study. Statistics of these eQTLs are summarized in Table 3 . No eQTLs were found for rs5848. Four eQTLs were found for both rs4747197 and rs660240, respectively. The eight eQTLs correspond to six unique genes. Two of these, PSAP and PSRC1, were represented by two correlated transcripts each [PSAP: r ¼ 0.82 in Sorbs, r ¼ 0.63 in LIFE-Heart, PSRC1: r ¼ 0.62 in Sorbs, r ¼ 0.61 in LIFE-Heart]. The strongest eQTLs of rs660240 and rs4747197 were ILMN_1671843 (PSRC1) and ILMN_1783149 (CDH23), respectively (Table 3 ).
In the next step, we analysed the correlation between expression levels of regulated genes and progranulin levels in 784 Sorbs and 882 individuals of LIFE-Heart for which both, gene-expression data and progranulin data were available. Four correlations were detected (Table 4) . Results for all eQTL transcripts can be found as Supplementary Material, Table S6 .
Whereas a significant inverse correlation of the two PSRC1 transcripts with progranulin was observed for both cohorts, a significant inverse correlation of PSAP and CDH23 transcripts was only observed in LIFE-Heart. For PSAP we observed an opposite trend in Sorbs while for CDH23 the trend was the same but failed to achieve statistical significance.
Mediation analysis of gene expression
The above-mentioned associations complete four association triangles of the form SNP ) progranulin, SNP ) gene expression, and finally, gene expression ) progranulin. The triangles have been used for Mendelian randomization to establish causal chains of the form SNP ) gene expression ) progranulin facilitating a mechanistic interpretation of the observed associations (Table 4 and Supplementary Material, Table S7 ). By Mendelian randomization analysis, causal effects of one of the PSRC1 transcripts (P ¼ 1.56 Â 10
À3
) and the PSAP transcript (P ¼ 4.01 Â 10 À2 ) were detected in the LIFE-Heart cohort suggesting mechanistic effects of the SNPs rs660240 and rs4747197, respectively. Moreover, PSRC1 explained part of the progranulin association of rs660240 (P ¼ 1.19 Â 10 À3 ). However, no causal effects could be inferred in the Sorbs cohort.
Causal inference of progranulin and related phenotypes
In the Sorbs cohort, we assessed whether the observed relations of progranulin with other obesity or metabolic traits studied in Table 1 are un-confounded, i.e. whether there is a causal link. We performed a Mendelian randomization analysis using rs660240 as instrumental variable. Significant causal relationships were observed for LDL-cholesterol (LDLC) (P ¼ 1.4 Â 10 À4 ), Table S8 ). Analysing LDLC in more detail, progranulin explained the observed association of rs660240 with LDLC (P ¼ 0.0033) but not vice versa (P ¼ 0.37).
Functional analyses of the PSRC1 locus
Based on eQTL and mediation analyses, we validated the most plausible target gene PSRC1 of the associated variant rs660240 by employing knockdown experiments in vitro. Treatment of murine 3T3-L1 preadipocytes with respective siRNA resulted in a >60% reduction in Psrc1 mRNA expression (Fig. 4) . Psrc1 knockdown led to a consecutive reduction in progranulin secretion of approximately 30% (Fig. 4) .
Discussion
In the present study, we performed a comprehensive genomewide meta-analysis of progranulin serum concentrations in three cohorts comprising a total sample size of 2811 individuals. Top-hits were replicated in two independent cohorts totaling 1, 800 samples. By this approach, we identified three genetic loci 
À8
Same effect alleles as in Table 2 were used.
robust associations with comparable effect sizes among all studies and combined P-values <2 Â 10
À12
. To unravel functional mechanisms, GWAS analyses were accompanied by genome-wide gene-expression analyses and corresponding mediation analyses. We found evidence for at least one causal chain where the SNP-effect is partly mediated by the expression of the gene. Finally, we performed functional studies in cell cultures which supported the role of PSRC1 in the regulation of progranulin secretion.
Progranulin is a secreted protein with important functions in several processes; including immune and inflammatory response and embryonic development (16) . It is implicated in various disease states such as cancers (17) , neurodegenerative diseases (18) and rheumatoid arthritis (19) . It has also been shown that serum progranulin is an adipokine induced by TNFa and dexamethasone which is increased in blood and adipose tissue of obese mouse models and which can be normalized with treatment of insulin-sensitizing agent pioglitazone (20) . Consistently, serum progranulin concentrations are increased in patients with type 2 diabetes (2). Our GWAS confirmed the CELSR2-PSRC1-MYBPHL-SORT1 locus carrying polymorphisms significantly associated with circulating progranulin with rs660240 as the strongest hit. The previous GWAS in 533 subjects by Carrasquillo et al. identified rs646776 near the sortilin gene (SORT1) as a regulator of progranulin levels in humans (11) . The authors supported their finding in vitro by showing that knockdown of SORT1 significantly increased extracellular progranulin levels in HeLa cells. Moreover, rs660240 is an eQTL of SORT1 in the liver (21) . Rs646776 is in strong LD with our top-hit rs660240 (r 2 >0.99). Therefore, our finding is consistent with the published GWAS with respect to the identified region. However, our data points to PSRC1 as additional, possibly independent candidate regulator of circulating progranulin: we found the top-hit rs660240 to be associated with PSRC1 expression in PBMCs and showed that the gene expression of PSRC1 is inversely correlated with progranulin. This association partly explained the observed SNP-progranulin association. According to GTEx database, rs660240 associates with the expression of PSRC1 in brain cortex, esophagus, liver, PBMC, pancreas, skin and testis too (22) . We observed a positive correlation of SORT1 and PSRC1 gene expression in blood. Yet, SORT1 gene expression in blood could not explain the SNP-progranulin association in our study. In line with this observation, the correlation of SORT1 and PSRC1 is markedly decreased if adjusting for confounders in our model (Supplementary Material, Fig. S1 ) further supporting an independent functional role of PSRC1, which was further addressed in in vitro knockdown experiments.
Summarizing these results, we suggest PSRC1 as another plausible candidate of the observed association of rs660240 with serum progranulin. It is possible that both candidate genes (PSRC1 and SORT1) are relevant in a tissue-specific manner as eQTLs of rs660240 and gene expressions of the genes are markedly different in various tissues (Supplementary Material,  Fig. S2 ). In line with this, PSRC1 and SORT1 were described as causally associated with cholesterol levels, obesity, diabetes and atherosclerosis suggested to operate in a conserved subnetwork in transcriptional networks in mouse and human (23) . Systematic functional studies targeting genes within this locus are warranted to unravel the contributions of these genes in more detail.
Using the RegulomeDB (24), we further prioritized which of the SNPs at the Chr. 1p31.1 locus that significantly associated with progranulin levels is most likely functionally relevant. According to RegulomeDB, rs12740374, which is in almost perfect LD with rs660240 (r 2 ¼0.996) and also strongly associated with progranulin in our data, is supposed to affect binding of multiple transcription factors, one of them TCF7L2, a wellestablished genetic risk factor for type 2 diabetes (24). Rs12740374 has also the strongest Eigen-PC score at this locus, a measure describing the functional relevance of an SNP (Supplementary Material, Table S2 ) (25) . Of note, PSRC1 encodes a proline-rich protein that is a target for regulation by the tumor suppressor protein p53 (26) . The encoded protein plays an important role in mitosis by recruiting and regulating microtubule depolymerases that destabilize microtubules (27, 28) . It remains to be determined whether progranulin's role in cancer development might be attributed to PSRC1 as would be suggested by these genetic findings.
Also noteworthy, despite missing genome-wide significance in the discovery meta-analysis, rs4747197 (in CDH23) and rs5848 (in GRN) showed consistent effects across all studies and were replicated in two independent German cohorts with robust combined P-values of 2.16 Â 10 À12 and 5.29 Â 10 À14 , respectively.
GRN encodes for granulin and is therefore a highly plausible candidate for the observed association. The corresponding SNP showed high values for the Eigen-PC corroborating a potential functional role of the mutation (Supplementary Material, Table S2 ). No eQTL effect of rs5848 on GRN expression was found in blood. The lack of eQTL-effects between the progranulin-associated SNPs and progranulin RNA levels might be attributed to the posttranslational progranulin modifications. Furthermore, it should be noted that the present study only tested the mRNA expression in PBMC whereas progranulin is prominently expressed also in other metabolically active organs such as adipose tissue or liver, so that potential eQTL-effects cannot be ruled out. Indeed, according to GTEx database, several eQTL-effects of rs5848 on GRN expression were observed in other tissues. The situation for the 10q22.1 locus (rs4747197) is less clear. First, this SNP showed the highest deleteriousness estimate of all associated SNPs of that locus underpinning its possible functional role (25) . The SNP maps within the coding sequence of CDH23. The strongest eQTL in blood was observed for CDH23 (29) . But another cis regulation (PSAP) and a variety of trans regulations were described for this SNP in the literature (30, 31) . In our data of Sorbs and LIFE-Heart, we confirmed the eQTLs of CDH23 (cis), PSAP (cis) and FAM188B (trans). Gene expression association analysis revealed an inverse correlation of PSAP with progranulin and evidence for causality was found by Mendelian randomization analysis in the LIFE-Heart cohort. This is in line with Zhou et al. who proposed PSAP as a regulator of progranulin in mice (32) and Nicholson et al. showing that PSAP influences monomer and oligomer composition of progranulin (33) .
In conclusion, the present meta-analysis is the largest GWAS of European cohorts targeting genes involved in progranulin regulation. Whereas the previously reported locus of rs660240 was confirmed already in our discovery meta-analysis, the geneexpression analysis and in vitro functional studies added a novel candidate gene (PSRC1) here. Two additional loci were established with robust genome-wide significance in the final meta-analysis. While for rs5848 GRN is the natural candidate, our eQTL and gene-expression association analyses suggest two plausible candidates for rs4747197, namely CDH23 as strongest eQTL or PSAP because of an inverse causal correlation with serum progranulin. Our data may promote new directions in progranulin research and so, in the pathophysiology of metabolic and neurodegenerative diseases, cancer and inflammation.
Materials and Methods
Subjects
Sorbs cohort
The cohort was recruited from the self-contained Sorbs population in Germany (34) (35) (36) (37) . Phenotyping included standardized questionnaires for past medical history and family history, measurement of anthropometric data [weight, height, waist-tohip ratio (WHR)], and an oral glucose tolerance test (OGTT). Glucose was quantified by the Hexokinase method (Automated Analyser Modular, Roche Diagnostics, Mannheim, Germany) and serum insulin was assessed using the AutoDELFIA Insulin assay (PerkinElmer Life and Analytical Sciences, Turku, Finland). Progranulin serum concentrations were measured using a commercially available ELISA kit (Progranulin human ELISA Kit AdipoGen, AdipoGen Inc., Korea) according to the manufacturer's instructions. Blood samples were taken in the morning after an overnight fast and stored at À80 C until analyses. The lowest level of progranulin detectable by the assay was 0.032 ng/ml. The degree of precision of the ELISA system in terms of coefficient of variance of intra-assay was 3-6.9% (6 samples tested 8 times), that of inter-assays was 4.7-7.3% (6 samples tested 5 times). Detailed phenotypic information is provided in Supplementary Material, Table S1 . The study was approved by the ethics committee of the University of Leipzig. Informed consent has been given by all participants before taking part in the study.
KORA
The Cooperative Health Research in the Region of Augsburg (KORA) study is a series of independent population-based epidemiological surveys and follow-up studies in the region of Augsburg in Germany. All participants are residents of German nationality identified through registration. All subjects gave written informed consent (38) . The present study includes data of the KORA follow-up study F4 (2006-2008) which has been approved by the local ethics committee. 1814 randomly selected participants of KORA F4 were selected for the genome-wide scan. 1628 subjects without type 2 diabetes were included in the present study. Progranulin serum concentrations were determined using a commercially available ELISA (Progranulin human ELISA Kit AdipoGen, AdipoGen Inc., Korea). Further phenotypic information is given in Supplementary Material, Table S1 .
Prevalence, prediction and prevention of diabetes -Botnia Study
The Prevalence, Prediction and Prevention of diabetes (PPP)-Botnia Study is a population-based study from the Botnia region of western Finland (39) . In the present study, 335 subjects with normal glucose tolerance from PPP that also participated in the Diabetes Genetics Initiative (DGI) were included (40) . Progranulin serum concentrations were measured using a commercially available ELISA kit (Mediagnost, Reutlingen, Germany).
The study was approved by the Ethics Committee of Helsinki University Hospital, Finland and all participants gave their written informed consent.
LIFE-Heart Study
This cohort includes individuals with suspected coronary artery disease due to clinical symptoms (non-invasive testing) assigned to coronary angiography. Details of the study can be found elsewhere (14) . Progranulin was measured by a commercially available ELISA (Mediagnost, Reutlingen, Germany) on the DSX automatic ELISA test system. The analytical sensitivity of the assay was 0.018 ng/ml. Intra and inter-assay coefficients of variation (N ¼ 16) were <5.7% at a concentration of 19.5 ng/ml and <4.4% at a concentration of 55.2 ng/ml progranulin and for a serum dilution of 1: 41.
The study has been approved by the Ethics Committee of the Medical Faculty of the University Leipzig, Germany (Reg. No 276-2005) and is registered at ClinicalTrials.gov (NCT00497887). Written informed consent was obtained from all participants before taking part in the study.
Berlin cohort (Metabolic Syndrome Berlin Potsdam)
This study was used as final replication stage according to our study design (Fig. 1 ). Subjects were recruited in a cross-sectional approach with focus on traits of the metabolic syndrome. Assessment of anthropometry included weight, height, waist and hip circumference, and skin fold measurements. All laboratory parameters were measured in fasting blood samples. A total of 833 Caucasian individuals from the MeSyBePo (Metabolic Syndrome Berlin Potsdam) study population from the region of Berlin/Potsdam, Germany, were included in the present study. Progranulin serum concentrations were measured using a commercially available ELISA kit (Mediagnost, Reutlingen, Germany).
The study was approved by the ethics committees of the University of Potsdam and the Charité -University (Medical Department), Berlin, Germany and all subjects gave written informed consent.
Phenotypic information of all cohorts is provided in Supplementary Material, Table S1 . We would like to acknowledge that progranulin serum levels vary between the study cohorts, which is in large part explained by different commercially available ELISAs used for measurement (Mediagnost Inc. for PPP, MeSyBePo and LIFE-Heart, Adipogen Inc. for KORA and Sorbs). Accordingly, values are more similar between cohorts using the same measurement technique.
Genotyping, quality control and genotype imputations
Sorbs cohort Genotyping was performed either by 500K Affymetrix GeneChip or by Affymetrix Genome-Wide Human SNP Array 6.0. The BRLMM algorithm (Affymetrix, Inc) was applied for the 500K array and the Birdseed algorithm was used for the GenomeWide Human SNP Array 6.0. Quality control was conducted as described previously (35) . Genotype imputation was performed separately for individuals genotyped with the two different assays using IMPUTE v2.1.2 (http://mathgen.stats.ox.ac.uk/ impute/impute_v2.html; date last accessed November 29, 2017). The reference panel was HapMap2 CEU, Release 24, dbSNP-build 126, NCBI 36. As proposed by Roshyara et al. (41) no SNP filtering was performed prior to imputation but a number of quality filters were applied thereafter (see Supplementary Material, Table  S1 for more details). We applied a 'drop one in' procedure to avoid bias by the relatedness structure within the Sorbs cohort (37). We performed one PCA for each Sorbian individual together with 50 most unrelated HapMap CEU individuals based on genotype data as explained in Gross et al. (35) . Resulting eigenvectors of CEU individuals were averaged over all iterations. Individuals were considered as ethnical outliers if the distance from the mean of the respective eigenvector of at least one of the first 10 eigenvectors exceeded 6 standard deviations. Based on these filters three individuals were discarded from association analysis (final N ¼ 974). A total of 848 non-diabetic subjects had combined genetic, progranulin and covariate data making them eligible for the first-stage GWAS. Details are provided in Supplementary Material, Table S1 .
KORA
Subjects were genotyped at the Helmholtz Genome Analysis Center using Affymetrix 6.0 arrays. The Birdseed 2 calling algorithm was applied. Imputations were conducted with IMPUTE v0.4.2 on HapMap Phase 2 CEU as a reference panel (Supplementary Material, Table S1 ). We applied the following post-imputation SNP filters: imputation quality r 2 !0.4, minor allele frequency > 1% and for called variants Callrate > 98% and P(HWE)>10
À6
.
PPP
Subjects were genotyped at the Broad Institute using the Affymetrix GeneChip V R Human Mapping 500K Array Set. The BRLMM algorithm was applied. Imputations were conducted with MACH on HapMap Phase 2 CEU as the reference panel (Supplementary Material, Table S1 ).
LIFE-Heart Study
Genotyping was performed using the Affymetrix Axiom Technology with custom option (Axiom-CADLIFE) or Axiom-CEU. Genotype calling was conducted with Affymetrix Power Tools version 1.17.0 and 1.16.1 respectively. Quality control criteria for individual samples included call rate (>97%), sex-mismatch, cryptic relatedness, and outliers of principal components analysis (6SD criterion of Eigenstrat software) (42) . SNP quality control comprised call rate !97%, Affymetrix cluster metrices as recommended by the company (FLD, HetSO, HomRO), P-value of exact Hardy-Weinberg equilibrium test !10 À6 , P-value of plate association !10 À7, and minor allele frequency >0%. For imputation, we used the intersection of QC SNPs of the two arrays. A total of 504 071 SNPs could be matched to the 1000Genomes reference phase 1, release 3 (http://math gen.stats.ox.ac.uk/impute/data_download_1000G_phase1_inte grated.html; date last accessed November 29, 2017). Imputation was performed using SHAPEIT v2 and IMPUTE2 v2.3.2.
A total of 5700 patients with genotype data were available. For 967 non-diabetic subjects, combined genotype, progranulin and covariate data were available for subsequent analysis. Since subjects included in this study were in part not fasting and were diagnosed with clinical coronary artery disease, we opted to use this sample as a replication cohort rather than including it in the meta-GWAS, although genome-wide data are available.
Berlin cohort (Metabolic Syndrome Berlin Potsdam-MeSyBePo) Selected SNPs were genotyped using the TaqMan V R SNP Genotyping assays according to the manufacturer's protocol (Applied Biosystems, Inc., Foster City, CA). To validate the reproducibility of genotyping, a random subset (about 5%) of the sample was re-genotyped. Genotypes matched in 100% of the samples. 833 individuals with both, genetic data and phenotypic traits including co-variables and progranulin measurements were available here.
Gene-expression studies
Gene-expression profiling in PBMCs in the Sorbs and LIFE-Heart PBMCs were extracted from blood samples. Gene expression was assessed using Illumina Human HT-12 v4 as described in detail elsewhere (29, 43) .
Pre-processing of RNA microarray data Pre-processing of RNA microarray data relied on the intensities of up to 47 323 transcripts derived from Illumina BeadStudio without background correction and normalization measured in 1029 individuals of the Sorbs cohort and 4509 individuals of the LIFE-Heart cohort. Pre-processing comprehended of (a) exclusion of individuals with an atypically low number of expressed genes [median -3 interquartile ranges (IQR) of the cohort's values], (b) quantile normalization and log2-transformation, (c) exclusion of individuals with atypical geneexpression profiles (Euclidian distance to average expression larger than median þ 3 or 4 IQR for Sorbs and LIFE-Heart, respectively) and excluding also individuals with atypical values of internal quality control-parameters (calculated as Mahalanobis distance of quality control probes included on the HT-12 v4 chip, a distance with a larger value than median þ 3 IQR was used as cut-off), (d) adjusting for batch effects due to different ybridization chips with Empirical Bayes estimates (44) . A total of 924 individuals from the Sorbs cohort and 4368 individuals of the LIFE-Heart cohort fulfilled all quality criteria.
Statistical analyses
Overall study design We performed a three stage association analysis. First, we performed a genome-wide meta-analysis of the cohorts Sorbs, KORA and PPP applying a less stringent cut-off of P < 5Â10
À5
. Top-hits of identified loci were replicated in the LIFE-Heart Study applying a P-value cut-off of P < 0.001. SNPs replicated with the same direction of effect were finally tested in MeSyBePo applying a stringent Bonferroni-corrected significance cut-off. Genome-wide association analysis was accompanied by eQTL and gene-expression association analysis of PBMCs in Sorbs and LIFE-Heart (Fig. 1) .
Association between circulating progranulin levels and anthropometric traits All non-normally distributed parameters were logarithmically transformed. Linear regression analyses adjusted for age, sex, and BMI (only age and sex for BMI analysis) were performed using SPSS software version 20.0 (SPSS, Chicago, IL). Since the discovered associations are potential sources of confounding, we performed additional adjustments of progranulin levels regarding these factors. This had no relevant impact on the association results of our top-hits (results not shown).
Genome-wide association analysis
Progranulin serum levels were log-transformed prior to analysis. Genetic associations were assessed using linear regression analyses of allele doses adjusted for age, sex and BMI. In the Sorbs cohort, we additionally adjusted for relatedness using mixed effect models (function 'polygenic' of the 'GenABEL' package of R) (12, 13) . Genome-wide analysis was performed in the studies Sorbs, KORA and PPP. For meta-analysis, SNPs with allele frequencies differing by more than 20% between cohorts and with violations of quality criteria in any of the studies were excluded resulting in a total of 2 069 113 SNPs analysed in the present study. Prior to meta-analysis, effect sizes of single studies were corrected for inflation by applying genomic control (Sorbs cohort: k ¼ 1.0, KORA: k ¼ 1.0, PPP: k ¼ 1.108). The relatively high inflation in PPP could not be explained by any kind of hidden sub-structure in the data and only appeared for this specific trait but not for others (43) . Standardized effects of single studies were combined using fixed and random effects models (function 'metagen' of the 'meta' package of R). P-values of both models are reported but the more conservative random effects models were used as primary selection criterion for subsequent replications. Q-statistics were applied to assess heterogeneity between studies.
Replication analysis LIFE-Heart Study. Top SNPs to be replicated in this cohort were retrieved from the LIFE-Heart Study genotype data. We analysed additive models of progranulin-SNP associations adjusting for age, sex and BMI as in the cohorts of the meta-analysis. We furthermore adjusted for fasting status and disease status (coronary artery disease case/control status). A P-value cut-off of 0.001 was applied at this stage.
BERLIN cohort (Metabolic Syndrome Berlin Potsdam). SNPs significant in LIFE-Heart (rs660240, rs4747197, rs5848) were de novo genotyped in this cohort. Associations were assessed for the additive mode of inheritance adjusting for age, sex and BMI.
Expression QTL analysis
The three successfully replicated SNPs rs660240, rs4747197 and rs5848 were subjected to genome-wide expression QTL (eQTL) analysis. For N ¼ 894 Sorbs and N ¼ 4299 LIFE-Heart samples, combined SNP and gene-expression data were available for that purpose. Gene-expression data were adjusted for age, sex, percentage of monocytes and lymphocytes. In the Sorbs we also adjusted for the relatedness structure. eQTLs were reported if achieving genome-wide significance in one of the cohorts (cis/ trans-specific false discovery rate of <5%) (29) and at least nominal significance in the other cohort. We also analysed whether our SNPs are in LD with eQTLs reported in the literature.
Mediation analysis
We tested whether the observed SNP-progranulin associations were mediated by gene expressions of the genes identified by our eQTL analyses. First, we analysed, whether the respective gene expressions are correlated with serum progranulin levels. Then, we performed a Mendelian randomization analysis of a causal (un-confounded) relation of the regulated PBMC gene-expression and progranulin serum levels using the corresponding eQTN (expression quantitative trait nucleotide) as instrumental variable. To account for possible direct SNP effects on progranulin, we modified the Mendelian randomization analyses accordingly (45) . From progranulin, we subtracted a potential direct SNP-effect, independent of the potential geneexpression effect, and performed Mendelian randomization analyses with the modified phenotype. In simulation analyses, this approach worked well when the direct SNP-effect was strong and the confounding of gene expression and target phenotype was weak. The latter is striven by adjusting progranulin and gene expression for their strongest co-variables as described above. Moreover, we tested whether the observed association between gene expression and progranulin explains at least part of the observed SNP to progranulin association. This is performed by analysing whether the absolute value of the beta coefficient of the SNP is reduced when gene expression is included into the regression model. Standard errors of the differences of corresponding beta coefficients were calculated by Jackknifing and one-sided tests were applied. A total of 784 Sorbs subjects and 882 LIFE-Heart patients were available for this type of analysis.
We also analysed the causal link between progranulin and a variety of obesity and metabolic traits (Table 1) by Mendelian randomization analyses. We used the SNP rs660240 showing the strongest association with progranulin as instrumental variable for that purpose. Here, a direct impact of the SNPs on the phenotypes of interest is less problematic since the SNP is not described as GWAS hit for most of the phenotypes considered in the present study. LDLC is an exception. Thus, we decided to use our above-mentioned strategy for that trait.
These analyses are considered as supplemental to our primary association analysis. Therefore, we refrained from correction for multiple testing here.
Functional consequences of the associated SNPs in RegulomeDB
Potential functional consequences of the associated SNPs were searched by using the RegulomeDB (24) . Briefly, RegulomeDB is a database that annotates SNPs with known and predicted regulatory elements in the human genome, such as DNAase hypersensitivity, binding sites of transcription factors, and promoter regions.
In vitro functional analyses
Small interfering RNA mediated knockdown of Psrc1 in vitro For RNAi mediated knockdown of Psrc1 the murine preadipocyte cell line 3T3-L1 was used. 3T3-L1 cells were maintained in DMEM supplemented with 10% fetal bovine serum. For knockdown, cells were seeded into 6-well plates and cultured for 48 h.
RNAi was performed using the FlexiTube GeneSolution GS84722 (Qiagen, Hilden, Germany). ON TARGET plus Accell GAPDH siRNA human served as positive control and ON TARGET plus Non-targeting pool was used as a negative control (both from Thermo Scientific, Schwerte, Germany). Transfection experiments were carried out using DharmaFECT1 (Thermo Scientific, Hilden, Germany) according to the manufacturer's instructions. Cells were transfected without (0 nM) or with 25 nM siRNA and incubated 48 h (for qPCR) or 72 h (for protein expression and secretion). Following incubation, supernatants were removed and cells were washed with PBS. Supernatants and cells were frozen in liquid nitrogen and stored at À80 C.
RNA extraction and quantitative real-time-PCR RNA was extracted using the InviTrap V R Spin Tissue RNA Mini Kit (STRATEC Molecular GmbH, Berlin, Germany). One mg of RNA was incubated with 0.5 mg random primers (Promega, Fitchburg, USA) in a total volume of 13.5 ml for 5 min at 70 C and cooled to 4 C. Following primer incubation, a mixture consisting of 200 U Moloney murine leukemia virus reverse transcriptase (Promega, Fitchburg, USA), 4 ml of 5xM-MLV-RT Buffer, 0.5 mM dNTPs (Promega, Fitchburg, USA) and 0.5 ml Ribolock RNase-Inhibitor (Thermo Scientific, Waltham, USA) was added. Reverse transcription was performed at 37 C for 60 min and 94 C for 5 min.
For the detection of murine Psrc1 gene expression the TaqMan probe Mm00498358_m1 (Life Technologies, Carlsbad, USA) was used according to the manufacture rs instructions. The expression of GAPDH or Psrc1 was calculated by the delta-delta CT method using ACTB or 36B4 as reference gene. Relative gene expression was compared with scrambled siRNA treated cells set as baseline level.
Progranulin measurements by ELISA For the detection of progranulin in supernatants of murine 3T3L-1 cells, the progranulin mouse ELISA kit (AdipoGen, Inc., Korea) was used. The degree of precision of the ELISA system in terms of intra-assay and inter-assay coefficient of variance (percentage) was less than 5.2% and 6.8%, respectively. Spike recovery and linearity were in a range of 90% to 103% and 0.3 to 0.6 lg/ml, respectively. Furthermore, the ELISA was specific for mouse progranulin and did not cross-react with rat or human progranulin. In addition, quality controls were included in all ELISA measurements, and results were within the expected range.
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